These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 27919182)

  • 1. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
    Howes OD; McCutcheon R; Agid O; de Bartolomeis A; van Beveren NJ; Birnbaum ML; Bloomfield MA; Bressan RA; Buchanan RW; Carpenter WT; Castle DJ; Citrome L; Daskalakis ZJ; Davidson M; Drake RJ; Dursun S; Ebdrup BH; Elkis H; Falkai P; Fleischacker WW; Gadelha A; Gaughran F; Glenthøj BY; Graff-Guerrero A; Hallak JE; Honer WG; Kennedy J; Kinon BJ; Lawrie SM; Lee J; Leweke FM; MacCabe JH; McNabb CB; Meltzer H; Möller HJ; Nakajima S; Pantelis C; Reis Marques T; Remington G; Rossell SL; Russell BR; Siu CO; Suzuki T; Sommer IE; Taylor D; Thomas N; Üçok A; Umbricht D; Walters JT; Kane J; Correll CU
    Am J Psychiatry; 2017 Mar; 174(3):216-229. PubMed ID: 27919182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.
    Wagner E; Kane JM; Correll CU; Howes O; Siskind D; Honer WG; Lee J; Falkai P; Schneider-Axmann T; Hasan A;
    Schizophr Bull; 2020 Dec; 46(6):1459-1470. PubMed ID: 32421188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving definition of treatment resistance.
    Peuskens J
    J Clin Psychiatry; 1999; 60 Suppl 12():4-8. PubMed ID: 10372602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia.
    Kane JM; Agid O; Baldwin ML; Howes O; Lindenmayer JP; Marder S; Olfson M; Potkin SG; Correll CU
    J Clin Psychiatry; 2019 Mar; 80(2):. PubMed ID: 30840788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
    Cipriani A; Boso M; Barbui C
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006324. PubMed ID: 19588385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2007 Sep; 95(1-3):39-47. PubMed ID: 17651943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis.
    Helfer B; Samara MT; Huhn M; Klupp E; Leucht C; Zhu Y; Engel RR; Leucht S
    Am J Psychiatry; 2016 Sep; 173(9):876-86. PubMed ID: 27282362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.
    Peuskens J; Kaufman L; Van Vleymen B
    Schizophr Res; 2007 Sep; 95(1-3):169-73. PubMed ID: 17630255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological treatment resistant schizophrenia].
    Cervera Enguix S; Seva Fernández A
    Actas Esp Psiquiatr; 2006; 34(1):48-54. PubMed ID: 16525905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success.
    Kane JM
    J Clin Psychiatry; 2013 Sep; 74(9):e18. PubMed ID: 24107769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
    Pickar D; Bartko JJ
    Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the concept of remission in schizophrenia.
    Leucht S; Beitinger R; Kissling W
    Psychopharmacology (Berl); 2007 Nov; 194(4):453-61. PubMed ID: 17618422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
    Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
    Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.